HEDS have authored five new reports for the National Institute for Health Research:
1. Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions [ID1150] September 2019
2. Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279] September 2019
3. Pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for
untreated metastatic squamous non-small-cell lung cancer [ID1306] September 2019
4.Pentosan polysulfate sodium for treating interstitial cystitis [ID1364] July 2019
5.Olaparib for maintenance treatment of BRCA-mutated ovarian,
fallopian tube and peritoneal cancer after response to first-line
platinum-based chemotherapy [ID1124] August 2019